EGFR and neoplasm: Importantly, ADAMTSL5 confers tumorigenicity by upregulating oncogenic inputs (i.e., MET, EGFR, PDGFRβ, IGF1Rβ, FGFR4), and its abrogation increases sensitivity of tumor cells to clinically relevant drugs (45).